Daten zum Projekt

Optimization of novel Respiratory Syncytial Virus-inhibitors by multi-parametric profiling (OPTIS)

Initiative: Innovative Ansätze in der antiviralen Wirkstoffentwicklung
Bewilligung: 28.06.2022
Laufzeit: 1 Jahr 3 Monate


The respiratory syncytial virus (RSV) is the causative agent of globally prevalent respiratory tract infections. Treatment options are limited: the standard-of-care consist of support with fluids and oxygen. To address this unmet medical need, the project team aims to develop innovative RSV fusion protein inhibitors with superior potency and resistance-breaking properties. In own preliminary work, the researchers have established an innovative multi-parametric workflow for the lead optimization of differentiated inhibitors. The chemical optimization is informed by structural biology and a phenotypic RSV drug-resistance assay panel. There is a high potential for the development of drugs that evade resistance. This project involves collaborations with a pharmaceutical company, which has discovered an exquisitely potent RSV entry inhibitor with a unique three-fold symmetry matching the homo-trimeric structure of the fusion protein target. Sharing the RSV candidates, expertise and assay capacities of the consortium with the RSV entry inhibitor maximizes the synergies to deliver pre-candidates. The nomination of pre-candidates will be based on a proof-of-concept in a well-established RSV in vivo model.


  • Prof. Dr. Thomas Pietschmann

    Medizinische Hochschule Hannover
    TWINCORE - Zentrum für experimentelle und
    klinische Infektionsforschung
    Experimentelle Virologie

  • Prof. Dr. Gesine Hansen

    Medizinische Hochschule Hannover
    Zentrum Kinderheilkunde und Jugendmedizin
    Klinik für Pädiatrische Pneumologie,
    Allergologie und Neonatologie

  • Prof. Dr. Thomas Krey

    Universität zu Lübeck
    Institut für Biochemie

  • Prof. Dr. Anna K. H. Hirsch

    Helmholtz-Institut für Pharmazeutische
    Forschung Saarland (HIPS)